PDCD1 and mucositis: The most common adverse reactions in the PD-1 inhibitor group were gastrointestinal reactions (40.0%), myelosuppression (31.2%), and oral mucositis (27.2%), all of which were higher than in the control group (4.4%, 5.1%, and 0%, respectively).